Tseng Yau-Lin, Chang Jia-Ming, Lai Wu-Wei, Chang Kung-Chao, Lee Shang-Chi, Lin Sheng-Hsiang, Yen Yi-Ting
From the Division of Thoracic Surgery (Y-LT, W-WL, Y-TY), Department of Surgery, National Cheng Kung University Hospital, College of Medical College, National Cheng Kung University, Tainan; Division of Thoracic Surgery (J-MC), Department of Surgery, Chia-Yi Christian Hospital, Chia-Yi; Department of Pathology (K-CC), National Cheng Kung University Hospital, College of Medical College, National Cheng Kung University; Biostatistics Consulting Center (S-CL), National Cheng Kung University Hospital, College of Medical College, National Cheng Kung University; and Institute of Clinical Medicine (S-HL, Y-TY), National Cheng Kung University, Tainan, Taiwan.
Medicine (Baltimore). 2015 Dec;94(52):e2278. doi: 10.1097/MD.0000000000002278.
We analyzed prognosticators for recurrence and post-recurrence survival in completely resected thymic epithelial tumors for the past 25 years in a single institution.Between June 1988 and December 2013, 238 patients undergoing intent-to-treat surgery for thymic epithelial tumors were reviewed. Sex, age, myasthenia gravis (MG), tumor histology, Masaoka staging, characteristic of locoregional invasion and recurrence, and the treatment for recurrence were collected. Comparison between groups was conducted using the Student t test and χ test. Survival analysis was performed using the Kaplan-Meier method and log-rank test. The Cox proportional hazards model was used for univariate and multivariate analyses of prognostic factors.One hundred sixteen of 135 patients with completely resected thymoma and 35 of 56 patients with thymic carcinoma remained free of recurrence. In patients with completely resected thymoma, Masaoka staging, MG, tumor invasion into the lung, pericardium, and innominate vein or superior vena cava (SVC) invasion were associated with recurrence-free survival in univariate analysis (P = 0.004, 0.003, 0.001, 0.007, and 0.039, respectively). In multivariate analysis, MG was the positive independent prognosticator (P = 0.039). In patients with completely resected thymic carcinoma, Masaoka staging and innominate vein or SVC invasion were associated with recurrence-free survival in univariate analysis (P = 0.045 and 0.005, respectively), whereas innominate vein or SVC invasion was the negative independent prognosticator (P = 0.012). In patients with recurrent thymoma, those treated with surgery followed by chemotherapy had a significantly better post-recurrence survival than those undergoing chemoradiotherapy (P = 0.029) and those without treatment (P = 0.007). Patients with recurrent thymic carcinoma undergoing surgery followed by chemotherapy had a significantly better post-recurrence survival than those without treatment (P = 0.004), but not significantly better than those undergoing chemoradiotherapy (P = 0.252).In patients with completely resected thymoma, MG was the positive independent prognosticators of recurrence-free survival. Surgery should be attempted for recurrent disease for better post-recurrence survival. In patients with completely resected thymic carcinoma, innominate vein or SVC invasion was the negative independent prognosticator. Surgery for recurrence could be considered since it provided benefit for post-recurrence survival as chemoradiotherapy did.
我们分析了过去25年在单一机构中完全切除的胸腺上皮肿瘤复发及复发后生存的预后因素。1988年6月至2013年12月期间,对238例行胸腺上皮肿瘤意向性治疗手术的患者进行了回顾性研究。收集了患者的性别、年龄、重症肌无力(MG)、肿瘤组织学、Masaoka分期、局部区域侵犯及复发特征以及复发后的治疗情况。组间比较采用Student t检验和χ检验。生存分析采用Kaplan-Meier法和对数秩检验。Cox比例风险模型用于预后因素的单因素和多因素分析。135例完全切除胸腺瘤的患者中有116例、56例胸腺癌患者中有35例未复发。在完全切除胸腺瘤的患者中,单因素分析显示Masaoka分期、MG、肿瘤侵犯肺、心包、无名静脉或上腔静脉(SVC)侵犯与无复发生存相关(P分别为0.004、0.003、0.001、0.007和0.039)。多因素分析中,MG是阳性独立预后因素(P = 0.039)。在完全切除胸腺癌的患者中,单因素分析显示Masaoka分期和无名静脉或SVC侵犯与无复发生存相关(P分别为0.045和0.005),而无名静脉或SVC侵犯是阴性独立预后因素(P = 0.012)。在复发性胸腺瘤患者中,接受手术继以化疗的患者复发后生存明显优于接受放化疗的患者(P = 0.029)和未治疗的患者(P = 0.007)。复发性胸腺癌接受手术继以化疗的患者复发后生存明显优于未治疗的患者(P = 0.004),但不比接受放化疗的患者明显更好(P = 0.252)。在完全切除胸腺瘤的患者中,MG是无复发生存的阳性独立预后因素。对于复发性疾病应尝试手术以获得更好的复发后生存。在完全切除胸腺癌的患者中,无名静脉或SVC侵犯是阴性独立预后因素。复发时可考虑手术,因为其与放化疗一样能为复发后生存带来益处。